INSR and neoplasm: Studies using a β-3 adrenergic receptor agonist to reduce circulating insulin levels or using a tyrosine kinase inhibitor that inhibited both the IR and IGF-1R reported reduced the tumor growth in MKR mice, further supporting our in vivo observation with DZ71–73.